News

CAR T-cell therapy eases SSc symptoms, early trial data show

A CAR T-cell therapy being developed by Bristol Myers Squibb eased skin thickness and improved lung function in people with systemic sclerosis (SSc), early trial data showed. These initial results for the treatment, BMS-986353, come from the Phase 1 Breakfree-1 clinical trial (NCT05869955), which is testing the therapy’s…

Milk-derived particles may offer treatment path for SSc fibrosis

Milk-derived extracellular vesicles — very small, natural particles from cow’s milk — were shown to safely reduce inflammation and scarring in a mouse model of systemic sclerosis (SSc). Because these vesicles carry molecules that can protect and help tissue repair itself, they “have attracted much attention due to their…

New skin markers help doctors refine dcSSc treatment prognosis

In people with diffuse cutaneous systemic sclerosis (dcSSc), certain skin features, including levels of specific molecules and cells, depend on disease duration, a study finds. These features, combined with disease duration, allowed researchers to predict patients’ response to mycophenolate mofetil (MMF), an immunosuppressive therapy commonly used for dcSSc. These…

Worsening breathing is key risk for people with SSc-ILD

More than a third of adults with systemic sclerosis (SSc) who develop interstitial lung disease (ILD) see their condition progress, and those who reported increasing shortness of breath in the past month had a higher risk of death — even if their breathing tests have not declined — an…

Anxiety levels may be slightly higher in scleroderma patients

People with scleroderma may have slightly elevated symptoms of anxiety compared to the general population, particularly those in specific sociodemographic subgroups, an international study reported. Researchers found that several demographic features, such as being younger or non-white, as well as disease features, including gastrointestinal symptoms, were associated with higher…

Self-reactive antibody levels linked to scleroderma progression: Study

Increasing levels of self-reactive antibodies in the bloodstream after the start of treatment are associated with the progression of systemic sclerosis (SSc), according to recent research. “We hypothesize that rising antibody [levels] during treatment may reflect ongoing immune activation, insufficient therapeutic response, or impending flare, whereas decreasing [levels] may…

Study links gut bacteria to severity of scleroderma-related ILD

The presence and severity of interstitial lung disease in people with systemic sclerosis (SSc) are associated with a specific combination of bacteria in the gut, a study suggests. “These species or their metabolic products may influence ILD [disease processes] and represent novel treatment targets,” the study’s researchers wrote. The…

New study finds sexual dysfunction is common in scleroderma

Sexual dysfunction is common among people with systemic scleroderma, but is rarely discussed between patients and their doctors, a new study shows. In the study, “Sexual dysfunction and perceptions of rheumatologist engagement on this issue in patients with systemic sclerosis,” the researchers said the reasons for…